By Ian Walker 
 

GlaxoSmithKline PLC said Wednesday that it has appointed Tony Wood as chief scientific officer from August, replacing Hal Barron, who will become nonexecutive director.

The pharmaceutical giant said Mr. Wood will assume full accountability for research and development on Aug. 1.

Mr. Wood joined the company in 2017 as senior vice president, medicinal science and technology, and has more than 30 years of experience in the industry.

Mr. Barron is stepping down from the role as he has been appointed CEO and board co-chair of Altos Labs.

"Altogether, these changes provide us with a clear pathway for continued momentum in R&D to deliver our new ambitions for growth and scale impact for patients," Chief Executive Emma Walmsley said.

 

Write to Ian Walker at ian.walker@wsj.com

 

(END) Dow Jones Newswires

January 19, 2022 02:32 ET (07:32 GMT)

Copyright (c) 2022 Dow Jones & Company, Inc.
Gsk (LSE:GSK)
Historical Stock Chart
From Apr 2022 to May 2022 Click Here for more Gsk Charts.
Gsk (LSE:GSK)
Historical Stock Chart
From May 2021 to May 2022 Click Here for more Gsk Charts.